Details for Patent: 12,629,377
✉ Email this page to a colleague
Which drugs does patent 12,629,377 protect, and when does it expire?
Patent 12,629,377 protects SUBVENITE and is included in one NDA.
Drugs Protected by US Patent 12,629,377
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF EPILEPSY AS ADJUNCTIVE THERAPY IN PATIENTS 2 YEARS AND OLDER WITH PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, OR GENERALIZED SEIZURES OF LENNOX-GASTAUT SYNDROME | ⤷ Start Trial | |||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | CONVERSION TO MONOTHERAPY IN ADULTS 16 YEARS AND OLDER WITH PARTIAL-ONSET SEIZURES WHO ARE RECEIVING CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, PRIMIDONE, OR VALPROATE AS THE SINGLE ANTIEPILEPTIC DRUG | ⤷ Start Trial | |||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
